Is Wall Street High Or Low On Provention Bio Inc. (PRVB)?


Provention Bio Inc. (NASDAQ:PRVB) finished Wednesday with an addition of $1.68 to close at $8.35, an upside of 25.19 percent. An average of 2,997,171 shares of common stock have been traded in the last five days. There was a gain of $1.97 in the past week, and it reached a new high 8 times over the past 12 months. The last 20 days have seen an average of 1,940,508 shares traded, while the 50-day average volume stands at 1,476,261.

PRVB stock has increased by 40.27% in the last month. The company shares reached their 1-month lowest point of $4.59 on 10/05/22. With the stock rallying to its 52-week high on 11/03/22, shares of the company touched a low of $3.18 and a high of $8.04 in 52 weeks. It has reached a new high 9 times so far this year and achieved 18.68% or $2.84 in price. In spite of this, the price is up 3.85% from the 52-week high.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


Valuation Metrics

Provention Bio Inc. (PRVB) stock’s beta is 2.30. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 195.70, the price-to-book (PB) ratio at 5.47.

Financial Health

The quick ratio of Provention Bio Inc. for the three months ended June 29 was 3.60, and the current ratio was 3.60, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $116.97 million compared to revenue of $1.4 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Provention Bio Inc.’s return on assets was -80.30%.

Earnings Surprise

For the three-month period that ended June 29, Provention Bio Inc. had $26.64 million in cash. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$29.69 million in the quarter, while revenues of -$21.97 million were grew 1.85%. The analyst consensus anticipated Provention Bio Inc.’s latest quarter earnings to come in at -$0.5 per share, but it turned out to be -$0.46, a 8.00% surprise. For the quarter, EBITDA amounted to -$29.56 million. Shareholders own equity worth $81.55 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Provention Bio Inc. (PRVB) price momentum. RSI 9-day as of the close on 02 November was 78.30%, suggesting the stock is Overbought, with historical volatility in this time frame at 122.12%.

As of today, PRVB’s price is $7.12 +30.48% or $1.97 from its 5-day moving average. PRVB is currently trading +35.93% higher than its 20-day SMA and +121.92% higher than its 100-day SMA. However, the stock’s current price level is +71.85% above the SMA50 and +93.48% above the SMA200.

The stochastic %K and %D were 50.08% and 43.79%, respectively, and the average true range (ATR) was 0.68. With the 14-day stochastic at 76.71% and the average true range at 0.61, the RSI (14) stands at 73.65%. The stock has reached 0.44 on the 9-day MACD Oscillator while the 14-day reading was at 0.51.

Analyst Ratings

Jefferies launched coverage on Provention Bio Inc. (NASDAQ: PRVB) in its analyst report released on September 20, 2022. The firm assigned the stock a Buy rating. The consensus rating for Provention Bio Inc. (PRVB) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell PRVB, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 7 others rate it as a “buy”.

What is PRVB’s price target for the next 12 months?

Analysts predict a range of price targets between $8.00 and $21.00, with a median target of $14.50. Taking a look at these predictions, the average price target given by analysts for Provention Bio Inc. (PRVB) stock is $14.50.


Please enter your comment!
Please enter your name here